Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
NFL Biosciences S.A. is a French biopharmaceutical company dedicated to the research and development of botanical drugs aimed at addressing addiction disorders, notably smoking cessation. Its primary focus is on its flagship product, NFL-101, which stands out due to its natural composition derived from a botanical extract intended to reduce the desire to smoke. NFL-101 aims to offer an alternative to traditional nicotine replacement therapies by providing a different mechanism of action that may appeal to users seeking a natural treatment avenue. Operating within the healthcare and pharmaceuticals sector, NFL Biosciences S.A. plays a crucial role in the ever-evolving field of addiction therapy, catering to a global demand for innovative solutions to combat cigarette addiction. Based in Montpellier, France, the company is strategically positioned to leverage its expertise in botanical research, potentially influencing shifts in smoking cessation strategies and contributing to public health objectives focused on reducing smoking-related diseases.
ROIC dropped from -299.79% to -314.25%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€3M
▼ -59.5% YoY
Op. Margin
—
ROIC
-314.25%
▼ -14.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow
N/A
Net Debt
-€2M
Net Cash Position
Cash & Equiv.
€2M
Continue Research